prednisolone has been researched along with Febrile Neutropenia in 6 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Febrile Neutropenia: Fever accompanied by a significant reduction in the number of NEUTROPHILS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide (Len) and dexamethasone (dex) therapy is a standard therapy in patients with multiple myeloma." | 9.34 | Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma. ( Ara, T; Fukuhara, O; Harigae, H; Ito, T; Katsuoka, Y; Kimura, T; Kobayashi, N; Minauchi, K; Nakajima, S; Noji, H; Onishi, Y; Ota, S; Sasaki, O; Yamamoto, J; Yokoyama, H, 2020) |
| "Lenalidomide (Len) and dexamethasone (dex) therapy is a standard therapy in patients with multiple myeloma." | 5.34 | Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma. ( Ara, T; Fukuhara, O; Harigae, H; Ito, T; Katsuoka, Y; Kimura, T; Kobayashi, N; Minauchi, K; Nakajima, S; Noji, H; Onishi, Y; Ota, S; Sasaki, O; Yamamoto, J; Yokoyama, H, 2020) |
| "Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP)." | 4.12 | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. ( Choi, YS; Do, YR; Eom, HS; Hyun, SY; Jeong, SH; Jo, JC; Kang, HJ; Kim, HJ; Kim, MK; Kim, SH; Kim, SJ; Kim, WS; Koh, Y; Kwak, JY; Kwon, JH; Lee, GW; Lee, HS; Lee, WS; Oh, SY; Park, BB; Park, Y; Shin, HJ; Sohn, BS; Suh, C; Won, JH; Yang, DH; Yi, JH; Yi, SY; Yoo, KH; Yoon, DH; Yun, HJ, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuda, K | 1 |
| Jo, T | 1 |
| Shimura, A | 1 |
| Honda, A | 1 |
| Taoka, K | 1 |
| Masamoto, Y | 1 |
| Matsui, H | 1 |
| Fushimi, K | 1 |
| Yasunaga, H | 1 |
| Kurokawa, M | 1 |
| Jeong, SH | 1 |
| Kim, SJ | 1 |
| Yoon, DH | 1 |
| Park, Y | 1 |
| Kang, HJ | 1 |
| Koh, Y | 1 |
| Lee, GW | 1 |
| Lee, WS | 1 |
| Yang, DH | 1 |
| Do, YR | 1 |
| Kim, MK | 1 |
| Yoo, KH | 1 |
| Choi, YS | 1 |
| Yun, HJ | 1 |
| Yi, JH | 1 |
| Jo, JC | 1 |
| Eom, HS | 1 |
| Kwak, JY | 1 |
| Shin, HJ | 1 |
| Park, BB | 1 |
| Hyun, SY | 1 |
| Yi, SY | 1 |
| Kwon, JH | 1 |
| Oh, SY | 1 |
| Kim, HJ | 1 |
| Sohn, BS | 1 |
| Won, JH | 1 |
| Kim, SH | 1 |
| Lee, HS | 1 |
| Suh, C | 1 |
| Kim, WS | 1 |
| Hisamatsu, Y | 1 |
| Morinaga, R | 1 |
| Watanabe, E | 1 |
| Ohtani, S | 1 |
| Shirao, K | 1 |
| Onishi, Y | 1 |
| Yokoyama, H | 1 |
| Katsuoka, Y | 1 |
| Ito, T | 1 |
| Kimura, T | 1 |
| Yamamoto, J | 1 |
| Nakajima, S | 1 |
| Sasaki, O | 1 |
| Ara, T | 1 |
| Minauchi, K | 1 |
| Fukuhara, O | 1 |
| Kobayashi, N | 1 |
| Noji, H | 1 |
| Ota, S | 1 |
| Harigae, H | 1 |
| Rulach, RJ | 1 |
| McKay, S | 1 |
| Neilson, S | 1 |
| White, L | 1 |
| Wallace, J | 1 |
| Carruthers, R | 1 |
| Lamb, C | 1 |
| Cascales, A | 1 |
| Marashi, H | 1 |
| Glen, H | 1 |
| Venugopal, B | 1 |
| Sadoyze, A | 1 |
| Sidek, N | 1 |
| Russell, JM | 1 |
| Alhasso, A | 1 |
| Dodds, D | 1 |
| Laskey, J | 1 |
| Jones, RJ | 1 |
| MacLeod, N | 1 |
| Elting, LS | 1 |
| Xu, Y | 1 |
| Chavez-MacGregor, M | 1 |
| Giordano, SH | 1 |
1 trial available for prednisolone and Febrile Neutropenia
| Article | Year |
|---|---|
Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
5 other studies available for prednisolone and Febrile Neutropenia
| Article | Year |
|---|---|
Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R-CHOP regimen: a nationwide real-world study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutrop | 2022 |
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutrop | 2022 |
Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab.
Topics: Adenocarcinoma of Lung; Adrenal Gland Neoplasms; Antineoplastic Agents, Immunological; Brain Neoplas | 2020 |
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemot | 2018 |
Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutrop | 2016 |